These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 25962253)

  • 21. Renal glucose reabsorption inhibitors to treat diabetes.
    Bailey CJ
    Trends Pharmacol Sci; 2011 Feb; 32(2):63-71. PubMed ID: 21211857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium glucose co-transporter 2 (SGLT2) inhibitors: new among antidiabetic drugs.
    Opie LH
    Cardiovasc Drugs Ther; 2014 Aug; 28(4):331-4. PubMed ID: 24825435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus.
    Kashiwagi A; Maegawa H
    J Diabetes Investig; 2017 Jul; 8(4):416-427. PubMed ID: 28178390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
    Lapuerta P; Zambrowicz B; Strumph P; Sands A
    Diab Vasc Dis Res; 2015 Mar; 12(2):101-10. PubMed ID: 25690134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Euglycemic ketoacidosis : a complication of SGLT2 inhibitors].
    Mizuno A; Lolachi S; Pernet A
    Rev Med Suisse; 2017 May; 13(565):1164-1167. PubMed ID: 28639760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sotagliflozin as a potential treatment for type 2 diabetes mellitus.
    Cariou B; Charbonnel B
    Expert Opin Investig Drugs; 2015; 24(12):1647-56. PubMed ID: 26548423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hemodynamic and renal implications of sodium-glucose cotransporter- 2 inhibitors in type 2 diabetes mellitus.
    Tejedor Jorge A
    Med Clin (Barc); 2016 Nov; 147 Suppl 1():35-43. PubMed ID: 28760224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus.
    Ribola FA; Cançado FB; Schoueri JH; De Toni VF; Medeiros VH; Feder D
    Eur Rev Med Pharmacol Sci; 2017 Jan; 21(1):199-211. PubMed ID: 28121337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and moderate renal function impairment: A systematic review and meta-analysis.
    Zhang L; Zhang M; Lv Q; Tong N
    Diabetes Res Clin Pract; 2018 Jun; 140():295-303. PubMed ID: 29649541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus.
    Scheen AJ
    Clin Pharmacokinet; 2014 Apr; 53(4):295-304. PubMed ID: 24420910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
    Vallon V; Thomson SC
    Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents.
    Washburn WN
    Expert Opin Ther Pat; 2012 May; 22(5):483-94. PubMed ID: 22583331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.
    Boyle LD; Wilding JP
    Expert Opin Emerg Drugs; 2013 Sep; 18(3):375-91. PubMed ID: 23968378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.
    Tsimihodimos V; Filippatos TD; Elisaf MS
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):399-408. PubMed ID: 27819144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Role of the kidneys in glucose homeostasis. Implication of sodium-glucose cotransporter 2 (SGLT2) in diabetes mellitus treatment].
    Girard J
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S35-S41. PubMed ID: 28577741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SGLT2 inhibitors: molecular design and potential differences in effect.
    Isaji M
    Kidney Int Suppl; 2011 Mar; (120):S14-9. PubMed ID: 21358697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Guthrie RM
    Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
    Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.